Johannes Drach

Johannes Drach

UNVERIFIED PROFILE

Are you Johannes Drach?   Register this Author

Register author
Johannes Drach

Johannes Drach

Publications by authors named "Johannes Drach"

Are you Johannes Drach?   Register this Author

66Publications

1216Reads

15Profile Views

Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience.

Oncology 2017 12;93(5):295-301. Epub 2017 Aug 12.

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/478265
Publisher Site
http://dx.doi.org/10.1159/000478265DOI Listing
March 2018

Novel agents have a significant impact on survival of patients with multiple myeloma.

Wien Klin Wochenschr 2015 Feb 22;127(3-4):92-7. Epub 2015 Jan 22.

Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-014-0605-6DOI Listing
February 2015

Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma.

Eur J Cancer 2014 Feb 15;50(3):622-7. Epub 2013 Nov 15.

Children's Cancer Research Institute, Vienna, Austria; Department of Pediatrics, Medical University Vienna, Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.10.013DOI Listing
February 2014

Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma.

J Proteome Res 2014 Feb 2;13(2):844-54. Epub 2013 Dec 2.

Faculty of Chemistry, Institute of Analytical Chemistry, University of Vienna , Währingerstraße 38, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/pr400881p
Publisher Site
http://dx.doi.org/10.1021/pr400881pDOI Listing
February 2014

Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma.

J Cancer Res Clin Oncol 2013 Oct 20;139(10):1771-5. Epub 2013 Jul 20.

Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-013-1475-4DOI Listing
October 2013

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

J Clin Oncol 2013 Oct 3;31(29):3688-95. Epub 2013 Sep 3.

Andre Goy, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack; Lei Zhang, Sherri Cicero, and Tommy Fu, Celgene, Summit, NJ; Rajni Sinha, Emory University Winship Cancer Institute, Atlanta, GA; Michael E. Williams, University of Virginia Health System, Charlottesville, VA; Sevgi Kalayoglu Besisik, Istanbul University Faculty of Medicine, Istanbul, Turkey; Johannes Drach, Medical University of Vienna, Vienna, Austria; Radhakrishnan Ramchandren, Karmanos Cancer Institute, Detroit, MI; and Thomas E. Witzig, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.2835DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879693PMC
October 2013

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Br J Haematol 2013 Mar 7;160(5):649-59. Epub 2013 Jan 7.

Department of Cellular Biotechnology and Haematology, Sapienza University of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12198DOI Listing
March 2013

Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws.

Head Neck 2012 Feb 11;34(2):194-200. Epub 2011 Mar 11.

University Clinic of Craniofacial, Maxillofacial and Oral Surgery, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hed.21708
Publisher Site
http://dx.doi.org/10.1002/hed.21708DOI Listing
February 2012

Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.

Clin Transpl 2009 :415-20

Division of Nephrology and Dialysis, Department of Medicine II, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
July 2010

Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.

Transplantation 2010 Jun;89(11):1385-90

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0b013e3181d9e1c0DOI Listing
June 2010

Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.

Ann Hematol 2010 Mar 20;89(3):273-82. Epub 2009 Aug 20.

Department Internal Medicine 3, Centre for Hematology and Medical Oncology, General Hospital Linz, Krankenhausstrasse 9, 4020, Linz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-009-0811-xDOI Listing
March 2010

Proteome maps of the main human peripheral blood constituents.

J Proteome Res 2009 Aug;8(8):3834-43

Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/pr801085gDOI Listing
August 2009

Lenalidomide: a new therapy for multiple myeloma.

Cancer Treat Rev 2008 May 29;34(3):283-91. Epub 2008 Jan 29.

Department of Hematology, University of Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2007.12.005DOI Listing
May 2008

Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.

Cancer Res 2008 Jan;68(1):44-54

Division of Oncology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-2531DOI Listing
January 2008

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.

Haematologica 2007 Oct;92(10):1411-4

Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Montleartstr. 37, 1170 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.11463DOI Listing
October 2007

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

Oncologist 2007 Mar;12(3):281-90

Institut Gustave-Roussy, Dept. of Medicine, 39 Rue Camille-Desmoulins, Villejuif Cedex 94805, France.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.12-3-281DOI Listing
March 2007

Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma.

Oncology 2005 16;69(6):499-502. Epub 2006 Jan 16.

Division of Bone Marrow Transplantation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/91031
Publisher Site
http://dx.doi.org/10.1159/000091031DOI Listing
March 2006

Further insights into multiple myeloma genetics.

Authors:
Johannes Drach

Haematologica 2006 Feb;91(2):147a

Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
February 2006

Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.

Leuk Res 2005 Dec 16;29(12):1473-7. Epub 2005 Jun 16.

Department of Internal Medicine I, Clinical Division of Oncology, Bone marrow transplantation and Hematology & Hemostaseology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2005.05.003DOI Listing
December 2005

Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.

Scand J Gastroenterol 2005 Oct;40(10):1222-5

Department of Medicine I, Medical University Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365520510023440DOI Listing
October 2005

Treatment of mantle cell lymphoma: targeting the microenvironment.

Expert Rev Anticancer Ther 2005 Jun;5(3):477-85

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer, Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.5.3.477DOI Listing
June 2005

Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report.

Hematol J 2004 ;5(4):361-3

Clinical Division of Oncology, Department of Medicine 1, University Hospital Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.thj.6200375DOI Listing
February 2005

Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.

Onkologie 2005 Feb;28(2):73-8

Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000083223DOI Listing
February 2005

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.

Blood 2004 Oct 27;104(8):2269-71. Epub 2004 May 27.

University Hospital Vienna, Department of Medicine I, Clinical Division of Oncology, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2004-03-10
Publisher Site
http://dx.doi.org/10.1182/blood-2004-03-1091DOI Listing
October 2004

Concomitant occurrence of MALT lymphoma and multiple myeloma.

Ann Hematol 2004 Sep 9;83(9):600-3. Epub 2004 Apr 9.

Clinical Division of Oncology, Department of Medicine I, University Hospital Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-004-0870-yDOI Listing
September 2004

DNA methylation profiles of lymphoid and hematopoietic malignancies.

Clin Cancer Res 2004 May;10(9):2928-35

Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

View Article

Download full-text PDF

Source
May 2004

Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.

Oncology 2003 ;65(4):306-10

Department of Internal Medicine I, Division of Oncology and Internal Medicine IV, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/74641
Publisher Site
http://dx.doi.org/10.1159/000074641DOI Listing
February 2004

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.

Eur J Haematol 2003 Sep;71(3):179-83

Department of Medicine I, Clinical Division of Oncology and Division of Hematology, University Hospital Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1600-0609.2003.00111.xDOI Listing
September 2003

Paraneoplastic pemphigus in association with hepatocellular carcinoma.

J Am Acad Dermatol 2003 Sep;49(3):538-40

Department of Dermatology, School of Medicine, University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1067/s0190-9622(03)01581-0DOI Listing
September 2003

New insights into the pathophysiology of multiple myeloma.

Lancet Oncol 2003 Sep;4(9):557-64

Department of Medicine, Clinical Division of Oncology, University Hospital, Vienna, Austria.

View Article

Download full-text PDF

Source
September 2003

Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma.

Clin Cancer Res 2003 Feb;9(2):820-6

Department of Medicine I, Clinical Division of Oncology, University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
February 2003

Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis.

Dig Dis Sci 2002 Sep;47(9):1909-14

Universitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1019623418063DOI Listing
September 2002

Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance.

Br J Haematol 2002 Jun;117(4):852-9

First Department of Internal Medicine and Medical Oncology, Wilhelminenspital, University of Vienna, Montleartstrasse 37, 1160 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2141.2002.03529.xDOI Listing
June 2002

Idiopathic eosinophilic endomyocarditis in the absence of peripheral eosinophilia.

Leuk Lymphoma 2002 Jan;43(1):215-8

Department of Cardiology, University of Vienna Medical School, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190210184DOI Listing
January 2002